<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057912</url>
  </required_header>
  <id_info>
    <org_study_id>2017CRISPR/Cas9&amp;TALEN</org_study_id>
    <nct_id>NCT03057912</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ</brief_title>
  <official_title>A Safety and Efficacy Study of Transcription Activator-like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jingchu University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label and triple cohort study of the safety and efficacy of TALEN and
      CRISPR/Cas9 to possibly treat HPV Persistency and human cervical intraepithelial
      neoplasiaⅠwithout invasion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HPV persistent infection is the major causal factor of cervical intraepithelial neoplasia
      (CIN) and cervical cancer. The important roles of E6 and E7 playing in HPV-driven
      carcinogenesis make them attractive targets for therapeutic interventions. Previous evidences
      showed that using designated TALEN and CRISPR/Cas9 as genome editing tool could produce
      disruption of HPV16 and HPV18 E6/E7 DNA, significantly decreasing the expression of E6/E7,
      inducing cell apoptosis and inhibiting cell lines growth.

      This study will evaluate the safety and efficacy of TALEN-HPV E6/E7 and CRISPR/Cas9-HPV E6/E7
      in treating HPV Persistency and HPV-related Cervical Intraepithelial NeoplasiaⅠ
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2018</start_date>
  <completion_date type="Anticipated">January 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>The primary objective of this Study is to evaluate the safety of therapeutic doses and the dosing regimen of TALEN and CRISPR/Cas9 plasmid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of HPV16 or 18 DNA titers</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Blood samples will be taken at the baseline, months 3 and 6 on each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of cervical cytological results.</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>ThinPrep Pap Test will be conducted at the baseline, months 3 and 6 on each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of cervical histological results.</measure>
    <time_frame>Baseline and 6 months.</time_frame>
    <description>Colposcopy Biopsy will be conducted at the baseline and month 6 on each subject.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Human Papillomavirus-Related Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>TALEN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRISPR/Cas9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TALEN</intervention_name>
    <description>TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.</description>
    <arm_group_label>TALEN</arm_group_label>
    <other_name>TALEN-HPV16 E6/E7;TALEN-HPV18 E6/E7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRISPR/Cas9</intervention_name>
    <description>CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.</description>
    <arm_group_label>CRISPR/Cas9</arm_group_label>
    <other_name>CRISPR/Cas9-HPV16 E6/E7T1;CRISPR/Cas9-HPV18 E6/ E7T2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HPV16 or HPV18 infection.

          -  Married and fertile, no fertility requirements.

          -  Without administration of hormone in the last six months.

          -  Subjects must be meet the ethical requirements and have signed informed consent.

        Exclusion Criteria:

          -  Pregnancy and breast feeding

          -  Any bacterial vaginitis

          -  Any Fungal vaginitis

          -  Any sexually transmitted diseases

          -  Active drug or alcohol abuse

          -  Any HPV medications within the past 12 weeks

          -  Allergy to active or non active ingredients in the study of drugs

          -  Cardiac insufficiency

          -  Liver and renal insufficiency

          -  Hypertension and severe complications

          -  Serious illness in past 30 days

          -  Currently participating in another clinical trial or any prior gene therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng Hu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Hu, M.D.</last_name>
    <phone>0086+18627803527</phone>
    <email>18627803527@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zheng Hu, M.D.</last_name>
      <phone>0086+18627803527</phone>
      <email>18627803527@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang C, Wang L, Jiang X, Shen H, He D, Li K, Xi L, Ma D, Wang H. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int. 2014;2014:612823. doi: 10.1155/2014/612823. Epub 2014 Jul 20.</citation>
    <PMID>25136604</PMID>
  </reference>
  <reference>
    <citation>Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, Zhang C, Wang L, Ji T, Liu D, He D, Xia X, Zhu T, Wei J, Wu P, Wang C, Xi L, Gao Q, Chen G, Liu R, Li K, Li S, Wang S, Zhou J, Ma D, Wang H. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest. 2015 Jan;125(1):425-36. doi: 10.1172/JCI78206. Epub 2014 Dec 15.</citation>
    <PMID>25500889</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Hu Zheng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cervical intraepithelial neoplasiaⅠ</keyword>
  <keyword>TALEN</keyword>
  <keyword>CRISPR/Cas9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

